AbbVie presents 22 IBD abstracts at ACG 2026, highlighting SKYRIZI and RINVOQ data
AbbVie disclosed 22 scientific abstracts at the American College of Gastroenterology 2026 meeting. The Phase 3 AFFIRM trial showed subcutaneous SKYRIZI achieved higher clinical remission and endoscopic response versus placebo in advanced therapy‑naïve Crohn’s disease. Long‑term extension data indicated 74.5% of fistulizing Crohn’s patients had no draining fistulas after five years, and real‑world evidence showed RINVOQ provided disease control in difficult‑to‑treat cases.
Why it matters
The data support AbbVie’s pending FDA application for subcutaneous SKYRIZI induction in Crohn’s disease and could strengthen market adoption of both drugs, potentially boosting AbbVie’s IBD revenue.
Key facts
- 1AbbVie presented 22 scientific abstracts from its IBD portfolio at the ACG 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9‑14. investingnews.com
- 2Phase 3 AFFIRM results showed SKYRIZI achieved significantly higher rates of clinical remission and endoscopic response versus placebo in advanced therapy‑naïve Crohn’s disease patients. investingnews.com
- 3Long‑term extension analyses demonstrated that 74.5% of patients with fistulizing Crohn’s disease had no draining fistulas after five years of SKYRIZI treatment. rttnews.com
- 4Real‑world studies reported disease control with RINVOQ in advanced, difficult‑to‑treat Crohn’s disease patients. investingnews.com
- 5AbbVie submitted an FDA application on April 27, 2026 for SKYRIZI subcutaneous induction for moderately to severely active Crohn’s disease. news.abbvie.com
- 6ABBV closed at $276.47, up 1.49% on the day of the announcement. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.